NASDAQ:MRTX - Mirati Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$44.35 +5.30 (+13.57 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$44.35
Today's Range$39.25 - $44.55
52-Week Range$2.70 - $44.55
Volume1.66 million shs
Average Volume319,744 shs
Market Capitalization$1.13 billion
P/E Ratio-15.95
Dividend YieldN/A
Beta2.22

About Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics logoMirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Debt-to-Equity RatioN/A
Current Ratio9.56
Quick Ratio9.56

Price-To-Earnings

Trailing P/E Ratio-15.95
Forward P/E Ratio-16.37
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.74 per share
Price / Book9.36

Profitability

EPS (Most Recent Fiscal Year)($2.78)
Net Income$-70,420,000.00
Net MarginsN/A
Return on Equity-62.28%
Return on Assets-55.07%

Miscellaneous

Employees51
Outstanding Shares29,050,000

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) posted its quarterly earnings results on Monday, May, 7th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.63) by $0.12. The biotechnology company earned $9.47 million during the quarter, compared to analysts' expectations of $10 million. View Mirati Therapeutics' Earnings History.

What price target have analysts set for MRTX?

10 analysts have issued 12-month price objectives for Mirati Therapeutics' stock. Their forecasts range from $5.00 to $44.00. On average, they anticipate Mirati Therapeutics' stock price to reach $25.4444 in the next twelve months. View Analyst Ratings for Mirati Therapeutics.

What are Wall Street analysts saying about Mirati Therapeutics stock?

Here are some recent quotes from research analysts about Mirati Therapeutics stock:
  • 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (5/9/2018)
  • 2. Cann analysts commented, "Mirati Therapeutics, Inc. announced today that it has entered into an exclusive license agreement with BeiGene for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati confirmed it will retain exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world." (1/8/2018)

Who are some of Mirati Therapeutics' key competitors?

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Dr. Rodney W. Lappe Ph.D., Exec. Chairman (Age 63)
  • Dr. Charles M. Baum M.D., Ph.D., Chief Exec. Officer, Pres and Director (Age 60)
  • Dr. James Christensen Ph.D., Chief Scientific Officer and Sr. VP (Age 50)
  • Dr. Isan Chen M.D., Chief Medical & Devel. Officer and Exec. VP (Age 56)
  • Mr. Jamie A. Donadio Ph.D., Chief Financial Officer and Sr. VP (Age 43)

Has Mirati Therapeutics been receiving favorable news coverage?

News articles about MRTX stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mirati Therapeutics earned a news impact score of 0.03 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.07 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.19%), Point72 Asset Management L.P. (1.40%), PointState Capital LP (1.03%), Farallon Capital Management LLC (0.93%), Rock Springs Capital Management LP (0.65%) and Acuta Capital Partners LLC (0.34%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum, Jamie A Donadio, Jamie Christensen, Ltd Braslyn, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

Which institutional investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Citigroup Inc. and Federated Investors Inc. PA. Company insiders that have sold Mirati Therapeutics company stock in the last year include Jamie A Donadio, Jamie Christensen and Tuesday Thirteen Inc. View Insider Buying and Selling for Mirati Therapeutics.

Which institutional investors are buying Mirati Therapeutics stock?

MRTX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., PointState Capital LP, Farallon Capital Management LLC, BlackRock Inc., Tibra Equities Europe Ltd, Iguana Healthcare Management LLC, UBS Group AG and Element Capital Management LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Charles M Baum, Ltd Braslyn and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $44.35.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $1.13 billion. The biotechnology company earns $-70,420,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Mirati Therapeutics employs 51 workers across the globe.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


MarketBeat Community Rating for Mirati Therapeutics (MRTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mirati Therapeutics (NASDAQ:MRTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Mirati Therapeutics in the last 12 months. Their average twelve-month price target is $25.4444, suggesting that the stock has a possible downside of 42.63%. The high price target for MRTX is $44.00 and the low price target for MRTX is $5.00. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.902.902.892.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.4444$25.4444$14.75$13.7143
Price Target Upside: 42.63% downside26.46% downside14.24% downside22.08% downside

Mirati Therapeutics (NASDAQ:MRTX) Consensus Price Target History

Price Target History for Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics (NASDAQ:MRTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/12/2018HC WainwrightBoost Price TargetBuy$40.00HighView Rating Details
3/12/2018BarclaysInitiated CoverageOverweight$44.00HighView Rating Details
3/9/2018SunTrust BanksBoost Price TargetPositive ➝ Buy$40.00HighView Rating Details
3/5/2018CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $37.00HighView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$18.00HighView Rating Details
1/8/2018CannReiterated RatingBuy$18.00HighView Rating Details
12/21/2017CowenInitiated CoverageOutperformLowView Rating Details
11/14/2017Leerink SwannUpgradeMarket Perform ➝ Outperform$9.00N/AView Rating Details
9/19/2017CIBCInitiated CoverageOutperform ➝ Outperform$18.00LowView Rating Details
8/4/2017Jefferies GroupSet Price TargetHold$5.00LowView Rating Details
11/18/2016Avondale PartnersDowngradeOutperform ➝ Market PerformN/AView Rating Details
11/4/2016WedbushReiterated RatingOutperform$12.00N/AView Rating Details
8/19/2016Piper Jaffray CompaniesReiterated RatingNeutralN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Mirati Therapeutics (NASDAQ:MRTX) Earnings History and Estimates Chart

Earnings by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics (NASDAQ:MRTX) Earnings Estimates

2018 EPS Consensus Estimate: ($3.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.90)($0.78)($0.82)
Q2 20183($0.86)($0.55)($0.75)
Q3 20184($0.85)($0.49)($0.68)
Q4 20183($0.88)($0.54)($0.75)

Mirati Therapeutics (NASDAQ MRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018Q1 2018($0.63)($0.51)$10.00 million$9.47 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.6130)($0.67)ViewN/AView Earnings Details
11/1/2017Q3 2017($0.8070)($0.65)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.81)($0.74)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.78)($0.73)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.97)($0.99)ViewN/AView Earnings Details
11/3/2016Q3 2016($1.15)($0.97)ViewN/AView Earnings Details
8/4/2016Q2($1.15)($1.11)ViewN/AView Earnings Details
5/5/2016Q1($0.99)($1.13)ViewN/AView Earnings Details
3/9/2016Q4($1.03)($0.96)ViewN/AView Earnings Details
11/6/2015Q3 2015($0.88)($1.11)ViewN/AView Earnings Details
8/6/2015Q2 2015($0.74)($0.95)ViewN/AView Earnings Details
5/6/2015Q1 2015($0.71)($0.77)ViewN/AView Earnings Details
3/11/2015Q414($1.00)($0.77)ViewN/AView Earnings Details
11/10/2014Q314($0.77)($0.72)ViewN/AView Earnings Details
8/8/2014Q214($0.69)($0.82)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.79)($1.01)ViewN/AView Earnings Details
3/18/2014Q413($0.66)($0.97)ViewN/AView Earnings Details
11/12/2013Q313($0.78)($2.95)ViewN/AView Earnings Details
8/12/2013Q2 2013($0.59)($0.81)ViewN/AView Earnings Details
5/13/2013Q1 2013($0.50)($1.00)ViewN/AView Earnings Details
3/13/2013Q4 2012($1.00)($1.00)ViewN/AView Earnings Details
11/14/2012Q3 2012($0.50)($1.00)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.50)($0.75)ViewN/AView Earnings Details
5/14/2012Q1 2012($0.50)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Mirati Therapeutics (NASDAQ:MRTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mirati Therapeutics (NASDAQ MRTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.86%
Institutional Ownership Percentage: 84.65%
Insider Trading History for Mirati Therapeutics (NASDAQ:MRTX)
Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics (NASDAQ MRTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2018Jamie A DonadioCFOSell12,100$35.00$423,500.0012,100View SEC Filing  
3/1/2018Jamie A DonadioCFOSell51,875$27.13$1,407,368.759,375View SEC Filing  
2/6/2018Jamie ChristensenSVPSell23,000$30.00$690,000.0010,877View SEC Filing  
1/26/2018Jamie ChristensenSVPSell12,500$26.11$326,375.0015,377View SEC Filing  
1/16/2018Jamie ChristensenSVPSell10,814$27.00$291,978.0013,691View SEC Filing  
1/11/2018Jamie ChristensenSVPSell14,725$22.99$338,527.756,395View SEC Filing  
11/16/2017Jamie ChristensenSVPSell10,275$18.00$184,950.0012,670View SEC Filing  
11/16/2017Venbio Select Advisor LlcMajor ShareholderBuy650,000$13.00$8,450,000.00View SEC Filing  
11/2/2017Jamie ChristensenSVPSell7,499$14.00$104,986.0010,169View SEC Filing  
10/4/2017Jamie ChristensenSVPSell4,000$14.00$56,000.00View SEC Filing  
9/21/2017Tuesday Thirteen Inc.Major ShareholderSell1,000$10.65$10,650.00View SEC Filing  
9/15/2017Jamie ChristensenSVPSell770$12.00$9,240.00View SEC Filing  
1/26/2017Ltd. BraslynMajor ShareholderBuy48,169$5.45$262,521.05View SEC Filing  
1/25/2017Ltd. BraslynMajor ShareholderBuy30,600$5.42$165,852.00View SEC Filing  
1/24/2017Ltd. BraslynMajor ShareholderBuy27,682$5.32$147,268.24View SEC Filing  
1/23/2017Ltd. BraslynMajor ShareholderBuy19,251$5.27$101,452.77View SEC Filing  
1/20/2017Ltd. BraslynMajor ShareholderBuy61,158$5.46$333,922.68View SEC Filing  
1/17/2017Ltd. BraslynMajor ShareholderBuy119,887$5.50$659,378.50View SEC Filing  
1/6/2017Boxer Capital, LlcMajor ShareholderBuy286,163$5.60$1,602,512.80View SEC Filing  
6/14/2016Charles M BaumCEOBuy20,000$7.05$141,000.0048,556View SEC Filing  
6/9/2016Bros. Advisors Lp BakerMajor ShareholderSell999,358$9.41$9,403,958.78137View SEC Filing  
6/7/2016Ltd. BraslynMajor ShareholderBuy376,902$9.96$3,753,943.92View SEC Filing  
5/6/2016Ltd. BraslynMajor ShareholderBuy65,782$18.21$1,197,890.22View SEC Filing  
3/28/2016Ltd. BraslynMajor ShareholderBuy20,848$19.36$403,617.28View SEC Filing  
3/18/2016Ltd. BraslynMajor ShareholderBuy1,166$19.34$22,550.44View SEC Filing  
1/15/2016Mark J. GergenCOOSell10,000$25.92$259,200.005,748View SEC Filing  
9/16/2015Bros. Advisors Lp BakerMajor ShareholderBuy150,000$45.00$6,750,000.00View SEC Filing  
5/26/2015Jamie ChristensenSVPSell4,750$28.07$133,332.50View SEC Filing  
3/5/2015Jamie ChristensenSVPSell6,000$25.41$152,460.00View SEC Filing  
2/19/2015Jamie ChristensenSVPSell4,750$22.84$108,490.00View SEC Filing  
2/3/2015Orbimed Advisors LlcMajor ShareholderBuy100,000$20.00$2,000,000.00View SEC Filing  
1/29/2015Bros. Advisors Lp BakerMajor ShareholderBuy425,000$20.00$8,500,000.00View SEC Filing  
7/1/2014Orbimed Advisors LlcMajor ShareholderSell107,332$21.66$2,324,811.12View SEC Filing  
11/26/2013Charles M BaumCEOBuy5,000$16.96$84,800.00View SEC Filing  
10/29/2013Orbimed Advisors LlcMajor ShareholderBuy125,000$17.50$2,187,500.00View SEC Filing  
10/24/2013Tang Capital Partners LpMajor ShareholderBuy57,143$17.50$1,000,002.50View SEC Filing  
9/20/2013Tang Capital Partners LpMajor ShareholderSell36,898$16.34$602,913.32View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mirati Therapeutics (NASDAQ MRTX) News Headlines

Source:
DateHeadline
Brokers Offer Predictions for Mirati Therapeutics Incs Q2 2018 Earnings (MRTX)Brokers Offer Predictions for Mirati Therapeutics Inc's Q2 2018 Earnings (MRTX)
www.americanbankingnews.com - May 11 at 8:34 AM
Jefferies Group Equities Analysts Increase Earnings Estimates for Mirati Therapeutics Inc (MRTX)Jefferies Group Equities Analysts Increase Earnings Estimates for Mirati Therapeutics Inc (MRTX)
www.americanbankingnews.com - May 10 at 9:36 AM
Q2 2018 EPS Estimates for Mirati Therapeutics Inc (MRTX) Cut by AnalystQ2 2018 EPS Estimates for Mirati Therapeutics Inc (MRTX) Cut by Analyst
www.americanbankingnews.com - May 10 at 6:36 AM
Q2 2018 EPS Estimates for Mirati Therapeutics Inc Cut by SunTrust Banks (MRTX)Q2 2018 EPS Estimates for Mirati Therapeutics Inc Cut by SunTrust Banks (MRTX)
www.americanbankingnews.com - May 10 at 6:36 AM
SunTrust Banks Comments on Mirati Therapeutics Incs FY2022 Earnings (MRTX)SunTrust Banks Comments on Mirati Therapeutics Inc's FY2022 Earnings (MRTX)
www.americanbankingnews.com - May 9 at 9:47 AM
Mirati Therapeutics (MRTX) Downgraded by Zacks Investment ResearchMirati Therapeutics (MRTX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 8:52 AM
Mirati Therapeutics (MRTX) Announces Quarterly  Earnings Results, Beats Estimates By $0.12 EPSMirati Therapeutics (MRTX) Announces Quarterly Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - May 8 at 10:28 AM
Mirati Therapeutics Reports First Quarter Financial ResultsMirati Therapeutics Reports First Quarter Financial Results
finance.yahoo.com - May 7 at 5:37 PM
Mirati: 1Q Earnings SnapshotMirati: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:37 PM
Mirati Therapeutics Inc (MRTX) Receives Average Rating of "Buy" from BrokeragesMirati Therapeutics Inc (MRTX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 6 at 10:19 AM
Contrasting Mirati Therapeutics (MRTX) & Eyenovia (EYEN)Contrasting Mirati Therapeutics (MRTX) & Eyenovia (EYEN)
www.americanbankingnews.com - May 5 at 11:23 AM
Mirati Therapeutics (MRTX) Raised to "Strong-Buy" at BidaskClubMirati Therapeutics (MRTX) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - May 5 at 12:11 AM
Equities Analysts Set Expectations for Mirati Therapeutics Incs Q1 2018 Earnings (MRTX)Equities Analysts Set Expectations for Mirati Therapeutics Inc's Q1 2018 Earnings (MRTX)
www.americanbankingnews.com - May 3 at 6:57 AM
ValuEngine Upgrades Mirati Therapeutics (MRTX) to Strong-BuyValuEngine Upgrades Mirati Therapeutics (MRTX) to Strong-Buy
www.americanbankingnews.com - May 2 at 11:38 PM
Can These Top-Performing Biotech Stocks Keep Climbing?Can These Top-Performing Biotech Stocks Keep Climbing?
finance.yahoo.com - April 30 at 5:14 PM
Mirati Therapeutics (MRTX) Reports Progress Of Lead Programs, Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination TrialsMirati Therapeutics (MRTX) Reports Progress Of Lead Programs, Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
www.streetinsider.com - April 25 at 5:28 PM
Mirati Therapeutics Target of Unusually High Options Trading (MRTX)Mirati Therapeutics Target of Unusually High Options Trading (MRTX)
www.americanbankingnews.com - April 25 at 7:36 AM
Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination TrialsMirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
finance.yahoo.com - April 24 at 5:35 PM
Mirati Therapeutics, Inc. (MRTX) Given Consensus Rating of "Buy" by BrokeragesMirati Therapeutics, Inc. (MRTX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 8:33 AM
Mirati Therapeutics (MRTX) Receives Buy Rating from SunTrust BanksMirati Therapeutics (MRTX) Receives Buy Rating from SunTrust Banks
www.americanbankingnews.com - April 8 at 2:04 PM
Mirati Therapeutics (MRTX) Upgraded by ValuEngine to "Buy"Mirati Therapeutics (MRTX) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - April 3 at 11:39 AM
Mirati Therapeutics (MRTX) Upgraded by Zacks Investment Research to "Hold"Mirati Therapeutics (MRTX) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 1 at 5:22 PM
Mirati Therapeutics (MRTX) Buy Rating Reiterated at HC WainwrightMirati Therapeutics' (MRTX) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 1 at 2:38 PM
Mirati Therapeutics (MRTX) PT Set at $18.00 by OppenheimerMirati Therapeutics (MRTX) PT Set at $18.00 by Oppenheimer
www.americanbankingnews.com - March 30 at 12:34 PM
HC Wainwright Boosts Mirati Therapeutics (MRTX) Price Target to $21.00HC Wainwright Boosts Mirati Therapeutics (MRTX) Price Target to $21.00
www.americanbankingnews.com - March 30 at 12:56 AM
Mirati Therapeutics (MRTX) Stock Rating Lowered by BidaskClubMirati Therapeutics (MRTX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 29 at 11:28 AM
Mirati Therapeutics (MRTX) Upgraded by BidaskClub to BuyMirati Therapeutics (MRTX) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 28 at 12:00 AM
Mirati Therapeutics (MRTX) Cut to Sell at Zacks Investment ResearchMirati Therapeutics (MRTX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 17 at 8:22 PM
Mirati Therapeutics, Inc. (MRTX) Receives Consensus Rating of "Buy" from BrokeragesMirati Therapeutics, Inc. (MRTX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 17 at 9:48 AM
Mirati Therapeutics, Inc. (MRTX) Expected to Post Quarterly Sales of $10.00 MillionMirati Therapeutics, Inc. (MRTX) Expected to Post Quarterly Sales of $10.00 Million
www.americanbankingnews.com - March 17 at 7:10 AM
Mirati Therapeutics (MRTX) Presents At Barclays Global Healthcare Conference 2018 - SlideshowMirati Therapeutics (MRTX) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 16 at 6:29 PM
Mirati Therapeutics (MRTX) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowMirati Therapeutics (MRTX) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 6:11 PM
Jamie A. Donadio Sells 12,100 Shares of Mirati Therapeutics, Inc. (MRTX) StockJamie A. Donadio Sells 12,100 Shares of Mirati Therapeutics, Inc. (MRTX) Stock
www.americanbankingnews.com - March 13 at 7:53 PM
32 Stocks Moving In Mondays Mid-Day Session | Benzinga - Benzinga32 Stocks Moving In Monday's Mid-Day Session | Benzinga - Benzinga
www.benzinga.com - March 13 at 8:26 AM
UPDATE: Barclays Starts Mirati Therapeutics, Inc. (MRTX) at Overweight - StreetInsider.comUPDATE: Barclays Starts Mirati Therapeutics, Inc. (MRTX) at Overweight - StreetInsider.com
www.streetinsider.com - March 13 at 8:26 AM
Traders Purchase Large Volume of Call Options on Mirati Therapeutics (MRTX)Traders Purchase Large Volume of Call Options on Mirati Therapeutics (MRTX)
www.americanbankingnews.com - March 13 at 7:28 AM
Mirati Therapeutics (MRTX) Research Coverage Started at BarclaysMirati Therapeutics (MRTX) Research Coverage Started at Barclays
www.americanbankingnews.com - March 12 at 10:28 PM
Mirati Therapeutics (MRTX) Price Target Increased to $40.00 by Analysts at HC WainwrightMirati Therapeutics (MRTX) Price Target Increased to $40.00 by Analysts at HC Wainwright
www.americanbankingnews.com - March 12 at 2:18 PM
Research Analysts Issue Forecasts for Mirati Therapeutics, Inc.s Q3 2018 Earnings (MRTX)Research Analysts Issue Forecasts for Mirati Therapeutics, Inc.'s Q3 2018 Earnings (MRTX)
www.americanbankingnews.com - March 12 at 4:00 AM
Mirati Therapeutics (MRTX) PT Raised to $40 at SunTrust Robinson HumphreyMirati Therapeutics (MRTX) PT Raised to $40 at SunTrust Robinson Humphrey
www.streetinsider.com - March 10 at 6:23 PM
SunTrust Banks Raises Mirati Therapeutics (MRTX) Price Target to $40.00SunTrust Banks Raises Mirati Therapeutics (MRTX) Price Target to $40.00
www.americanbankingnews.com - March 9 at 9:02 PM
Did Mirati Therapeutics Inc’s (NASDAQ:MRTX) Recent Earnings Growth Beat The Trend?Did Mirati Therapeutics Inc’s (NASDAQ:MRTX) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - March 9 at 6:49 PM
Mirati Therapeutics (MRTX) Posts  Earnings Results, Misses Estimates By $0.06 EPSMirati Therapeutics (MRTX) Posts Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - March 9 at 4:11 PM
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results - PR Newswire (press release)Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 8 at 6:42 PM
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial ResultsMirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
finance.yahoo.com - March 8 at 6:42 PM
Mirati Therapeutics To Present At Upcoming Healthcare Conferences - PR Newswire (press release)Mirati Therapeutics To Present At Upcoming Healthcare Conferences - PR Newswire (press release)
www.prnewswire.com - March 8 at 8:24 AM
Royce & Associates LP Sells 130,000 Shares of Mirati Therapeutics, Inc. (MRTX)Royce & Associates LP Sells 130,000 Shares of Mirati Therapeutics, Inc. (MRTX)
www.americanbankingnews.com - March 6 at 10:53 AM
Citigroup Boosts Mirati Therapeutics (MRTX) Price Target to $37.00Citigroup Boosts Mirati Therapeutics (MRTX) Price Target to $37.00
www.americanbankingnews.com - March 5 at 2:59 PM
Bogle Investment Management L P DE Acquires Shares of 137,671 Mirati Therapeutics, Inc. (MRTX)Bogle Investment Management L P DE Acquires Shares of 137,671 Mirati Therapeutics, Inc. (MRTX)
www.americanbankingnews.com - March 5 at 5:10 AM
Mirati Therapeutics, Inc. (MRTX) CFO Jamie A. Donadio Sells 51,875 SharesMirati Therapeutics, Inc. (MRTX) CFO Jamie A. Donadio Sells 51,875 Shares
www.americanbankingnews.com - March 2 at 9:23 PM

SEC Filings

Mirati Therapeutics (NASDAQ:MRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mirati Therapeutics (NASDAQ:MRTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mirati Therapeutics (NASDAQ MRTX) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.